Loading...

We've got a brand new version of Simply Wall St! Try it out

ICC International Cannabis

CNSX:WRLD.U
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
WRLD.U
CNSX
$32M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

ICC International Cannabis Corp., through its subsidiaries, engages in the cannabis business in Canada and internationally. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • ICC International Cannabis has significant price volatility in the past 3 months.
WRLD.U Share Price and Events
7 Day Returns
-25%
CNSX:WRLD.U
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-92.1%
CNSX:WRLD.U
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
WRLD.U Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ICC International Cannabis (WRLD.U) -25% -25% -74.3% -92.1% -43.8% -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • WRLD.U underperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • WRLD.U underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
WRLD.U
Industry
5yr Volatility vs Market

Value

 Is ICC International Cannabis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ICC International Cannabis. This is due to cash flow or dividend data being unavailable. The share price is $0.045.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ICC International Cannabis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ICC International Cannabis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:WRLD.U PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-05-31) in CAD CA$-0.44
CNSX:WRLD.U Share Price ** CNSX (2019-09-20) in USD $0.05
CNSX:WRLD.U Share Price converted to CAD reporting currency Exchange rate (USD/ CAD) 1.326 CA$0.06
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ICC International Cannabis.

CNSX:WRLD.U PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:WRLD.U Share Price ÷ EPS (both in CAD)

= 0.06 ÷ -0.44

-0.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ICC International Cannabis is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • ICC International Cannabis is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does ICC International Cannabis's expected growth come at a high price?
Raw Data
CNSX:WRLD.U PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ICC International Cannabis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ICC International Cannabis's assets?
Raw Data
CNSX:WRLD.U PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-05-31) in CAD CA$0.22
CNSX:WRLD.U Share Price * CNSX (2019-09-20) in USD $0.05
CNSX:WRLD.U Share Price converted to CAD reporting currency Exchange rate (USD/ CAD) 1.326 CA$0.06
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:WRLD.U PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:WRLD.U Share Price ÷ Book Value per Share (both in CAD)

= 0.06 ÷ 0.22

0.28x

* Primary Listing of ICC International Cannabis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ICC International Cannabis is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess ICC International Cannabis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. ICC International Cannabis has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ICC International Cannabis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ICC International Cannabis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ICC International Cannabis expected to grow at an attractive rate?
  • Unable to compare ICC International Cannabis's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare ICC International Cannabis's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare ICC International Cannabis's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:WRLD.U Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:WRLD.U Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:WRLD.U Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-05-31 -15 -113
2019-02-28 -8 -60
2018-11-30 -5 -16
2018-08-31 -3 -6
2018-05-31 -3 -1
2018-02-28 0 -1
2017-11-30 0 0
2017-08-31 0 -1
2017-05-31 0 -1
2017-02-28 0 -1
2016-11-30 0 0 -1
2016-08-31 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if ICC International Cannabis is high growth as no earnings estimate data is available.
  • Unable to determine if ICC International Cannabis is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:WRLD.U Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from ICC International Cannabis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:WRLD.U Past Financials Data
Date (Data in CAD Millions) EPS *
2019-05-31 -0.44
2019-02-28 -0.37
2018-11-30 -0.16
2018-08-31 -0.12
2018-05-31 -0.05
2018-02-28 -0.06
2017-11-30 -0.02
2017-08-31 -0.05
2017-05-31 -0.06
2017-02-28 -0.07
2016-11-30 -0.07
2016-08-31 -0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ICC International Cannabis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. ICC International Cannabis's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. ICC International Cannabis's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess ICC International Cannabis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ICC International Cannabis has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ICC International Cannabis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ICC International Cannabis's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ICC International Cannabis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ICC International Cannabis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ICC International Cannabis's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
ICC International Cannabis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ICC International Cannabis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:WRLD.U Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-05-31 -112.98 46.87 5.10
2019-02-28 -60.31 36.75 4.69
2018-11-30 -16.41 16.22
2018-08-31 -6.14 6.09
2018-05-31 -1.03 1.00
2018-02-28 -0.99 0.95
2017-11-30 -0.36 0.21
2017-08-31 -0.62 0.22
2017-05-31 -0.81 0.40
2017-02-28 -0.78 0.38
2016-11-30 0.00 -0.76 0.47
2016-08-31 0.05 -0.44 0.42
2016-05-31 0.05 -0.26 0.26
2016-02-29 0.05 -0.30 0.29
2015-11-30 0.05 -0.31 0.29
2015-08-31 -0.35 0.31
2015-05-31 -0.40 0.36
2015-02-28 -0.55 0.50
2014-11-30 -0.46 0.42
2014-08-31 -0.39 0.35
2014-05-31 -0.29 0.26
2014-02-28 -0.11 0.09
2013-11-30 -0.12 0.09
2013-08-31 -0.17 0.13
2013-05-31 -0.21 0.17
2013-02-28 -0.26 0.20
2012-11-30 -0.28 0.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ICC International Cannabis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ICC International Cannabis has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ICC International Cannabis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ICC International Cannabis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ICC International Cannabis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ICC International Cannabis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ICC International Cannabis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ICC International Cannabis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ICC International Cannabis's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of ICC International Cannabis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ICC International Cannabis Company Filings, last reported 3 months ago.

CNSX:WRLD.U Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-05-31 145.83 28.23 5.47
2019-02-28 62.84 5.49 1.29
2018-11-30 110.73 3.73 2.95
2018-08-31 69.35 0.00 0.41
2018-05-31 3.82 0.02 1.63
2018-02-28 -0.10 0.02 0.07
2017-11-30 -0.02 0.02 0.09
2017-08-31 -0.07 0.02 0.15
2017-05-31 -0.29 0.01 0.00
2017-02-28 -0.27 0.02 0.01
2016-11-30 -0.16 0.01 0.00
2016-08-31 0.21 0.01 0.02
2016-05-31 -0.03 0.01 0.00
2016-02-29 0.00 0.01 0.01
2015-11-30 0.04 0.03 0.15
2015-08-31 0.07 0.03 0.23
2015-05-31 0.15 0.02 0.25
2015-02-28 0.19 0.00 0.01
2014-11-30 0.27 0.00 0.08
2014-08-31 0.02 0.00 0.02
2014-05-31 0.13 0.00 0.19
2014-02-28 -0.03 0.00 0.03
2013-11-30 -0.04 0.00 0.00
2013-08-31 -0.03 0.00 0.02
2013-05-31 -0.05 0.00 0.01
2013-02-28 -0.02 0.00 0.01
2012-11-30 -0.13 0.00 0.01
  • ICC International Cannabis's level of debt (19.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if ICC International Cannabis's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ICC International Cannabis has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if ICC International Cannabis has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess ICC International Cannabis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ICC International Cannabis has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ICC International Cannabis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ICC International Cannabis dividends.
If you bought $2,000 of ICC International Cannabis shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ICC International Cannabis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ICC International Cannabis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:WRLD.U Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ICC International Cannabis has not reported any payouts.
  • Unable to verify if ICC International Cannabis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ICC International Cannabis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ICC International Cannabis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ICC International Cannabis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ICC International Cannabis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ICC International Cannabis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ICC International Cannabis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Shpilt
AGE 40
TENURE AS CEO 0.4 years
CEO Bio

Mr. David Shpilt serves as Chief Executive Officer and Director of Patient Services at Plants Not Pills. Mr. Shpilt serves as a Chief Executive Officer at ICC International Cannabis Corp. since joined it on April 15, 2019. Mr. Shpilt is a highly sought after expert in the medical cannabis industry in Canada, having founded MMG, Medical Marijuana Group, an expert legal and medical consulting services firm. He served as Vice President of Clinical Business Development of Abba Medix Group Inc. He is also a retired Board Certified Pedorthist and a Manual Osteopathic Practitioner where he first began to work in a clinical setting. Subsequently, he has owned and operated companies supplying durable medical equipment, orthopedic appliances and devices to both the Public and Private sectors under contracts and on the open market. He successfully started 14 clinics across Ontario over 9 years, all of which remain highly viable to this date. He served as a Director of Canada House Wellness Group Inc. since 2016 until April 2017. He served as a Director at Abba Medix Group Inc. since May 19, 2016. Mr. Shpilt, an early-mover in the cannabis space, has pioneered novel and first-of-their-kind solutions across various strata - from seed to sale to patient care. The results of these activities, some of which are highlighted below, have manifested into a breadth and depth of knowledge, as well as a rolodex in the cannabis industry that serves ICC tremendously as it moves forward. Highlights of Mr. Shpilt's successful businesses, monetizations and exits in the cannabis sector over the last half-decade include: Founding of over 12 patient clinics across Canada, with over 100,000 cannabis prescriptions filled to meet the needs of Canadians;Building of several contract manufacturing and white label facilities in Canada, the United States and Europe, providing best of breed THC and CBD products derived from both cannabis and industrial hemp;Creation of genetics libraries which confront and prosecute a wide variety of maladies, and branding of selfsame into recognized product lines, including two of the top eight rated strains on Lift & Co.;Early stage application for and the subsequent granting of multiple commercial licenses under Health Canada’s Federal framework for licensed production (Cannabis Act, ACMPR and MMPR); and, Development of premium targeted brands for Licensed Producers (“LPs”), including the industry’s first three white label cannabis product lines; two of which were developed specifically to aid Canadian Military Veterans suffering from PTSD, chronic pain and other diagnosed medical conditions.

CEO Compensation
  • Insufficient data for David to compare compensation growth.
  • Insufficient data for David to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure of the ICC International Cannabis management team in years:

0.4
Average Tenure
  • The average tenure for the ICC International Cannabis management team is less than 2 years, this suggests a new team.
Management Team

David Shpilt

TITLE
Chief Executive Officer
AGE
40
TENURE
0.4 yrs

Peter Nguyen

TITLE
CFO & Director
TENURE
1.3 yrs

Jonathan Beland

TITLE
Vice President of Corporate Development
TENURE
0.4 yrs

Lauren Magda

TITLE
Chief of Staff
TENURE
0.4 yrs

Catherine McClusky

TITLE
Consultant
COMPENSATION
CA$2K
AGE
66
TENURE
5.4 yrs
Board of Directors Tenure

Average tenure of the ICC International Cannabis board of directors in years:

1.3
Average Tenure
  • The average tenure for the ICC International Cannabis board of directors is less than 3 years, this suggests a new board.
Board of Directors

Peter Nguyen

TITLE
CFO & Director
TENURE
0.3 yrs

Julio Viskovich

TITLE
Member of Advisory Board
TENURE
4.8 yrs

Neill Franklin

TITLE
Member of Advisory Board
TENURE
4.6 yrs

Elaine Alec

TITLE
Member of Advisory Board

Michael Rigato

TITLE
Member of Advisory Board

Stacy Quinney

TITLE
Member of Advisory Board
AGE
49
TENURE
3.6 yrs

Eugene Beukman

TITLE
Director
AGE
61
TENURE
1.4 yrs

Brendan Purdy

TITLE
Director
TENURE
1.3 yrs

Matt Christopherson

TITLE
Member of Advisory Board
TENURE
0.8 yrs

Matthew Fish

TITLE
Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
06. Oct 18 Sell Peter Nguyen Individual 04. Oct 18 05. Oct 18 -25,000 $0.66 $-16,103
05. Oct 18 Buy Peter Nguyen Individual 02. Oct 18 02. Oct 18 25,000 $0.59 $14,830
X
Management checks
We assess ICC International Cannabis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ICC International Cannabis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

ICC International Cannabis Corp., through its subsidiaries, engages in the cannabis business in Canada and internationally. It holds a license to cultivate, manufacture, supply, hold, import, export, and transport cannabis and derivative products; and engages in procuring and distributing medical cannabis products and cannabis derivatives. ICC International Cannabis Corp. has strategic partnerships with Green Tree International Inc., Auxly Cananbis Group Inc., Affinity Alpha Unit, Authentic Brands Group, and Biotii Technologies Corp. The company was formerly known as Kaneh Bosm BioTechnology Inc. and changed its name to ICC International Cannabis Corp. in September 2018. ICC International Cannabis Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Details
Name: ICC International Cannabis Corp.
WRLD.U
Exchange: CNSX
Founded: 2006
$31,734,267
705,205,955
Website: http://www.intlcannabiscorp.com
Address: ICC International Cannabis Corp.
789 West Pender Street,
Suite 810,
Vancouver,
British Columbia, V6C 1H2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX WRLD.U Common Shares Canadian National Stock Exchange CA USD 27. Nov 2014
OTCPK WLDC.F Common Shares Pink Sheets LLC US USD 27. Nov 2014
DB 8K51 Common Shares Deutsche Boerse AG DE EUR 27. Nov 2014
DB 8K51 COM NPV (POST REV SPLT) Deutsche Boerse AG DE EUR 22. Sep 2019
Number of employees
Current staff
Staff numbers
0
ICC International Cannabis employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:40
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/07/29
Last earnings reported: 2019/05/31
Last annual earnings reported: 2019/02/28


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.